RBC
NVO

Ronald Blue & Co’s Novo Nordisk NVO Stock Holding History

Ronald Blue & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,788
Closed -$237K – 259
2017
Q1 		$237K Buy
+13,788
New +$240K 0.01% 184
2015
Q4 		– Sell
-25,178
Closed -$683K – 268
2015
Q3 		$683K Sell
25,178
-5,230
-17% -$148K 0.04% 102
2015
Q2 		$833K Buy
30,408
+2,496
+9% +$70.2K 0.04% 104
2015
Q1 		$745K Buy
27,912
+3,396
+14% +$78.2K 0.04% 120
2014
Q4 		$519K Sell
24,516
-4,616
-16% -$103K 0.03% 155
2014
Q3 		$693K Buy
29,132
+412
+1% +$9.48K 0.05% 118
2014
Q2 		$663K Buy
28,720
+3,812
+15% +$84.2K 0.04% 135
2014
Q1 		$569K Sell
24,908
-442
-2% -$9.42K 0.04% 142
2013
Q4 		$469K Buy
25,350
+4,160
+20% +$72.5K 0.03% 156
2013
Q3 		$359K Buy
21,190
+20,890
+6,963% +$351K 0.03% 170
2013
Q2 		$5K Buy
+300
New +$4.99K ﹤0.01% 234

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Ronald Blue & Co's NVO Position: Q2 2017 in Review

Ronald Blue & Co sold out of Novo Nordisk (NVO) in Q2 2017, closing a stake of 13,788 shares — an estimated $237K sold.

Ronald Blue & Co first reported a position in NVO in Q2 2013 and held it in 11 quarters. The position peaked at $833K in Q2 2015. 484 funds tracked by Wall St. Rank hold NVO as of Q2 2017.

  • Ronald Blue & Co reported no remaining Novo Nordisk position as of Q2 2017 after selling out during the quarter.
  • Ronald Blue & Co sold 13,788 Novo Nordisk shares in Q2 2017, an estimated $237K.
  • Ronald Blue & Co first reported a position in Novo Nordisk in Q2 2013 and held it in 11 quarters.
  • Ronald Blue & Co's Novo Nordisk position peaked at $833K in Q2 2015.
  • 484 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2017.

Based on Ronald Blue & Co's 13F filing for Q2 2017, filed 28 Jul 2017.